Cellares signs first Asian manufacturing deal with Taiwan's GenomeFrontier Therapeutics for CAR-T production

Cellares announced a new partnership with Taiwanese biotech GenomeFrontier Therapeutics, marking the manufacturer’s first collaboration in Asia. The agreement will see Cellares evaluate and potentially produce GenomeFrontier’s CAR‑T cell therapies.

The deal expands Cellares’ global manufacturing footprint and aligns with its strategy to support emerging cell therapy developers. Details on the scope of manufacturing services and timelines were not disclosed.

Alongside the Cellares‑GenomeFrontier contract, Ori Biotech also reported new cell therapy manufacturing agreements, though specifics were not provided in the brief report. The announcements were part of a broader industry update that included news from Reckitt, Astellas and Hovione.

These partnerships underscore growing demand for specialized manufacturing capacity as more cell‑based treatments advance toward clinical use.